Carbopol

The present investigation has been undertaken with aim to formulation and evaluation of etoricoxib gel with different gelling agent and different penetration enhancer. Etoricoxib is highly selective cyclooxygenase-2 (COX-2) inhibitor. In this present study gel with carbopol, HPMC and Na-CMC as gelling agent prepared with different penetration enhancer like propyl glycol, oleic acid. Menthol oil. Formulation were evaluated for pH, stability study, spreadibilty, extrudabilty, bioadhesive (ex-vivo), skin irritation, viscosity, appearance and In-vitro drug diffusion. The formulation of Etoricoxib topical gel was prepared using carbopol, HPMC and Na-cmc in three batches A, B and C. With the consideration of all formulation characteristic and parameter we selected batch-A formulation for further study of anti-inflammatory and anti-analgesic activity. It was concluded that the Etoricoxib gel formulation containing carbopol with increase concentration of propyl glycol 10% and 2% oleic acid (OA) was suitable for topical application and it shows comparable result with market product and shows much better result of formulation, anti-inflammatory and anti-analgesic activity.

The study aimed to formulate and evaluate sustained release ondansetron tablet. Conventional ondansetron tablets not only produce rapid and relatively high peak blood levels resulting in adverse effects but also should be administered three to four times daily. These drawn backs can be overcome by designing a suitable sustained release formulation. Sustained release tablets of ondansetron to be taken once daily were formulated with ondansetron hydrochloride equivalent to 8 mg of ondansetron base. Matrix system based on swellable as well as non-swellable polymers was selected for sustaining the drug release. Different polymers such as hydroxypropylmethylcellulose (HPMC), Carbopol were studied. Combinations of non-swellable polymers with HPMC were also tried in order to get the desired sustained release profile over a period of 24 h. The effect of drug to polymer ratio on in vitro release was studied. The marketed formulation was evaluated for different parameters such as appearance, weight variation, drug content and in vitro drug release. The optimized formulation was subjected to stability studies at different temperature and humidity conditions as per ICH guidelines. In vivo studies were carried out for the optimized formulation in six healthy human volunteers and the pharmacokinetic parameters.